SANOFI CONS HEALTHC IND L
Sanofi Consumer Healthcare India Limited operates as a fast-moving consumer healthcare company in India. It offers products in the allergy, physical wellness, and pain care segments under brands, such as Allegra, Combiflam, Avil, DePURA, Festal, and Novalgin NU through distributors, wholesalers, government institutions and hospitals, pharmacies, pharmacy chains, and e-commerce. The company was in… Read more
SANOFI CONS HEALTHC IND L (SANOFICONR) - Net Assets
Latest net assets as of December 2025: ₹3.84 Billion INR
Based on the latest financial reports, SANOFI CONS HEALTHC IND L (SANOFICONR) has net assets worth ₹3.84 Billion INR as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₹5.47 Billion) and total liabilities (₹1.63 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₹3.84 Billion |
| % of Total Assets | 70.2% |
| Annual Growth Rate | 35.98% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 4.58 |
SANOFI CONS HEALTHC IND L - Net Assets Trend (2023–2025)
This chart illustrates how SANOFI CONS HEALTHC IND L's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for SANOFI CONS HEALTHC IND L (2023–2025)
The table below shows the annual net assets of SANOFI CONS HEALTHC IND L from 2023 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | ₹3.84 Billion | +40.66% |
| 2024-12-31 | ₹2.73 Billion | +31.50% |
| 2023-12-31 | ₹2.08 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to SANOFI CONS HEALTHC IND L's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 0.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ₹230.00 Million | 5.99% |
| Other Components | ₹3.61 Billion | 94.01% |
| Total Equity | ₹3.84 Billion | 100.00% |
SANOFI CONS HEALTHC IND L Competitors by Market Cap
The table below lists competitors of SANOFI CONS HEALTHC IND L ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
CAC Nantong Chemical Co., Ltd.
SHE:301665
|
$324.14 Million |
|
Clearfield Inc
NASDAQ:CLFD
|
$324.21 Million |
|
BR Advisory Partners
SA:BRBI11
|
$324.30 Million |
|
LiaonWellhope Agri-Tech Co Ltd
SHG:603609
|
$324.40 Million |
|
Hubei Guochuang Hi-tech Material Co Ltd
SHE:002377
|
$324.05 Million |
|
SNDL Inc.
NASDAQ:SNDL
|
$323.90 Million |
|
SF Urban Properties AG
SW:SFPN
|
$323.88 Million |
|
Audinate Group Limited
PINK:AUDGF
|
$323.81 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in SANOFI CONS HEALTHC IND L's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,730,000,000 to 3,840,000,000, a change of 1,110,000,000 (40.7%).
- Net income of 2,401,000,000 contributed positively to equity growth.
- Dividend payments of 1,267,000,000 reduced retained earnings.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₹2.40 Billion | +62.53% |
| Dividends Paid | ₹1.27 Billion | -32.99% |
| Other Changes | ₹-24.00 Million | -0.62% |
| Total Change | ₹- | 40.66% |
Book Value vs Market Value Analysis
This analysis compares SANOFI CONS HEALTHC IND L's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 25.60x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 47.36x to 25.60x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2023-12-31 | ₹90.14 | ₹4269.10 | x |
| 2024-12-31 | ₹118.54 | ₹4269.10 | x |
| 2025-12-31 | ₹166.76 | ₹4269.10 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently SANOFI CONS HEALTHC IND L utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 62.53%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 27.33%
- • Asset Turnover: 1.61x
- • Equity Multiplier: 1.42x
- Recent ROE (62.53%) is below the historical average (69.42%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2023 | 79.43% | 30.30% | 1.58x | 1.66x | ₹1.44 Billion |
| 2024 | 66.30% | 24.98% | 1.68x | 1.58x | ₹1.54 Billion |
| 2025 | 62.53% | 27.33% | 1.61x | 1.42x | ₹2.02 Billion |
Industry Comparison
This section compares SANOFI CONS HEALTHC IND L's net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $6,324,899,570
- Average return on equity (ROE) among peers: 17.23%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| SANOFI CONS HEALTHC IND L (SANOFICONR) | ₹3.84 Billion | 79.43% | 0.42x | $324.08 Million |
| GlaxoSmithKline Pharmaceuticals Limited (GLAXO) | $16.96 Billion | 22.18% | 0.80x | $1.19 Billion |
| Kopran Limited (KOPRAN) | $1.09 Billion | 9.86% | 1.43x | $34.19 Million |
| Marksans Pharma Limited (MARKSANS) | $9.05 Billion | 26.35% | 0.36x | $428.52 Million |
| NGL Fine-Chem Limited (NGLFINE) | $160.59 Million | 15.04% | 1.05x | $39.88 Million |
| Pfizer Limited (PFIZER) | $9.01 Billion | 33.25% | 0.22x | $818.67 Million |
| Sanofi India Limited (SANOFI) | $17.36 Billion | 17.53% | 0.46x | $376.73 Million |
| SENORES PHARMACEUTICALS L (SENORES) | $94.96 Million | 7.21% | 0.53x | $157.65 Million |
| SMS Pharmaceuticals Limited (SMSPHARMA) | $2.22 Billion | 9.19% | 1.30x | $105.56 Million |
| TTK Healthcare Limited (TTKHLTCARE) | $982.22 Million | 14.46% | 1.13x | $31.85 Million |